» Authors » Ran Abuhasira

Ran Abuhasira

Explore the profile of Ran Abuhasira including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 34
Citations 311
Followers 0
Related Specialties
Top 10 Co-Authors
Published In
Affiliations
Soon will be listed here.
Recent Articles
1.
Brikman S, Tannous H, Novofastovski I, Abuhasira R, Mader R, Bieber A
J Clin Rheumatol . 2025 Feb; PMID: 39993209
Objective: Previous studies have shown an association between chondrocalcinosis (CC) and vascular calcifications (VCs). This study aimed to investigate the association of VCs detected on joint radiographs (XRs) of older...
2.
Azuly H, Shafat T, Grupel D, Porges T, Abuhasira R, Belkin A, et al.
Infect Dis Ther . 2024 Dec; 14(1):167-180. PMID: 39652286
Introduction: Despite the declining public health emergency status, COVID-19 still poses significant risks, especially for immunocompromised individuals. We aimed to evaluate the effectiveness of tixagevimab-cilgavimab (T-C) prophylaxis in preventing severe...
3.
Gabbay J, Walter E, Kerman T, Amitai N, Gabay O, Hazan I, et al.
PLoS One . 2024 Nov; 19(11):e0313098. PMID: 39585890
Background: Non-arteritic anterior ischemic optic neuropathy (NAION) is a leading cause of acute optic nerve damage. While cardiovascular risk factors such as hypertension, diabetes mellitus, and obstructive sleep apnea are...
4.
Gozlan A, Abuhasira R, Dreiher J, Peleg S, Sebbag G, Schwarzfuchs D, et al.
Isr J Health Policy Res . 2024 Nov; 13(1):67. PMID: 39529194
Background: Mass Casualty Incidents (MCIs) pose significant challenges for healthcare systems. While policies are typically crafted based on past experiences, the lessons learned from each incident play a crucial role...
5.
Abuhasira R, Burrack N, Turjeman A, Patt Y, Leibovici L, Grossman A
Am J Med . 2024 Oct; 138(3):449-457.e7. PMID: 39424213
Background: The best first-line monotherapy for hypertension remains uncertain, as current guidelines suggest that thiazides, angiotensin-converting enzyme inhibitors (ACEis), angiotensin receptor blockers (ARBs), and calcium channel blockers (CCBs) are appropriate...
6.
Zeller L, Ben David R, Novack L, Abuhasira R, Abu-Shakra M, Miskin Y, et al.
Ther Adv Musculoskelet Dis . 2024 Oct; 16:1759720X241274032. PMID: 39391091
Background: The incidence of various types of vasculitis conditions over time, specifically during coronavirus disease 2019 (COVID-19), is unknown. Objectives: We aimed to assess recent trends in vasculitides and the...
7.
Abuhasira R
Eur J Intern Med . 2024 Sep; 129:28-29. PMID: 39244394
No abstract available.
8.
Brikman S, Serfaty L, Abuhasira R, Schlesinger N, Bieber A, Rappoport N
Rheumatology (Oxford) . 2024 Jun; 63(9):2411-2417. PMID: 38895877
Objective: To develop a machine learning-based prediction model for identifying hyperuricemic participants at risk of developing gout. Methods: A retrospective nationwide Israeli cohort study used the Clalit Health Insurance database...
9.
Rhein A, Rabinovich A, Abuhasira R, Lubaton-Barshishat S, Erez O
Res Pract Thromb Haemost . 2024 May; 8(4):102430. PMID: 38798792
Background: Antiphospholipid syndrome (APS) can present with either a thromboembolic event (thrombotic APS, TAPS) or an obstetric complication (obstetric APS, OAPS). Data on long-term complications in the different APS phenotypes...
10.
Goldbart A, Abuhasira R, Shiloh A, Even-Tsur J, Tarasiuk A
Am J Respir Crit Care Med . 2024 Feb; 209(10):1261-1263. PMID: 38417070
No abstract available.